de Boer Daniel Anton
Transaction: 07/31/2026
BUY
Change
+200,000
Price
$1.77
Filing
08/03/2026
Type
BUY
ProQR Therapeutics N.V.
PRQR • Biotechnology
$1.38
— 0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$145.40M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 62.5%Manageable debt level · 0.28Healthy liquidity · 3.09Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:58 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.38
Change0.00%
Shares Out105.36M
Market Cap$145.40M
52W Range1.33 - 3.10
Beta0.03
P/E-2.02
P/S53.30
P/B2.93
P/FCF-9.58
EV/Sales38.81
EV/EBITDA-6.09
Price$1.38
Change0.00%
Shares Out105.36M
Market Cap$145.40M
52W Range1.33 - 3.10
Beta0.03
P/E-2.02
P/S53.30
P/B2.93
P/FCF-9.58
EV/Sales38.81
EV/EBITDA-6.09
EV/FCF-6.98
Earnings Yield-12.35%
FCF Yield-10.44%
Dividend Yield0.00%
Gross Margin83.01%
Oper. Margin-2.76%
Profit Margin-2.65%
Debt/Eq0.28
Current Ratio3.09
Quick Ratio3.09
Target$3.00
Target Upside117.39%
Target Median$3.00
Target Range3.00 - 3.00
Volume599.63K
Avg Volume930.30K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
49
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
46/100
Why this score▼
Positive revenue growth · 62.5%Manageable debt level · 0.28Healthy liquidity · 3.09Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 12 analyst votes · 2026-10-20
96/100
Bullish
Bullish
11
Hold
1
Bearish
0
Price Target
2026-08-14
Low
$3.00
Mean
$3.00
Median
$3.00
High
$3.00
Insider Transactions
Recent executive and insider activity
Filius Bart
Transaction: 07/17/2026
BUY
Change
+150,000
Price
$1.72
Filing
07/21/2026
Type
BUY
de Boer Daniel Anton
Transaction: 07/09/2026
BUY
Change
+150,000
Price
$1.74
Filing
07/13/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| de Boer Daniel Anton | BUY | +200,000 | $1.77 | 07/31/2026 | 08/03/2026 |
| Filius Bart | BUY | +150,000 | $1.72 | 07/17/2026 | 07/21/2026 |
| de Boer Daniel Anton | BUY | +150,000 | $1.74 | 07/09/2026 | 07/13/2026 |
| de Boer Daniel Anton | BUY | +150,000 | $1.59 | 07/07/2026 | 07/08/2026 |
| Filius Bart | BUY | +150,000 | $1.54 | 06/26/2026 | 06/30/2026 |
| Hinsch Gylvin Lykke | BUY | +14,595 | $1.42 | 06/02/2026 | 06/30/2026 |
| Hinsch Gylvin Lykke | OTHER | 0 | Not reported | 06/02/2026 | 06/02/2026 |
| Shannon James Samuel | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| Shannon James Samuel | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Carreno-Gomez Begona | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| de Boer Daniel Anton | OTHER | +595,644 | $2.02 | 03/18/2026 | 03/18/2026 |
| Filius Bart | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| HEGGIE THERESA | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| HEGGIE THERESA | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Hom Dennis | OTHER | +250,000 | $2.02 | 03/18/2026 | 03/18/2026 |
| Lawton Alison Frances | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| Maier Martin Alexander | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |
| Platenburg Gerardus Johannes | OTHER | +186,139 | $2.02 | 03/18/2026 | 03/18/2026 |
| Platenburg Gerardus Johannes | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Valerio Domenico | OTHER | +25,192 | $2.02 | 03/18/2026 | 03/18/2026 |